WinstonWınston
Back
Alexander's logo

Alexander's

ALX
50
REIT - Retail · Real Estate
Price
$265.03
-7.23 (-2.66%)
Market Cap
$1.35B
Exchange
New York Stock Exchange
Winston Score
50
Winston is curious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Strong
Growth
Mixed
Cash Flow
Weak
Stability
Weak
Valuation
Good
Dividends
Good

Winston Score History

The full picture

Alexander's, Inc. is a real estate investment trust (REIT) based in New York that owns and leases commercial properties in the New York City metropolitan area. The company does not develop or sell homes — it owns office buildings, retail spaces, and mixed-use properties and rents them out to tenants. Its most important asset is 731 Lexington Avenue in Manhattan, a large mixed-use tower that is home to Bloomberg L.P. as its anchor tenant.

Alexander's makes money by collecting rent from its tenants under long-term lease agreements. The company is very small compared to most REITs, owning only a handful of properties, all concentrated in the New York City area. Vornado Realty Trust manages the properties and holds a significant ownership stake, which ties Alexander's fate closely to Vornado's decisions. The biggest risk the company faces is its heavy dependence on Bloomberg as a tenant — if Bloomberg were to reduce or exit its lease, revenue would drop sharply.

Share count broadly stable

+0.2% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 5.1M (2021) → 5.1M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
100.0%
Premium pricing power — 100.0% gross margin
Profit after running costs
Operating Margin
30.1%
Excellent — 30.1% operating margin
Return on the money invested
ROCE
5.8%
Weak — 5.8% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-1.5%
Shrinking sales (-1.5% YoY)
Profit growth
EPS YoY
+354.0%
Earnings growing fast (+354.0% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
1/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
16%
Weak — only 16% of profit becomes cash
Spare cash per sale
FCF Margin
9.6%
Modest free cash flow (9.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
3.73
Heavy debt load (3.73)
Covers its interest
Interest Cover
1.24x
Dangerous — barely covers interest (1.2x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
8.0x
Attractive valuation — P/E 8.0

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year
P/E vs Forward
-15.0
SLOWING
Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
6.60%
Healthy income — 6.60% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record
Dividend Growth
+0.0%
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial